What is Lenvima (lenvatinib) used for?
Lenvima is the brand name for lenvatinib, an oral anticancer medicine in the tyrosine kinase inhibitor (TKI) class. It is used to treat certain cancers, including:
- Differentiated thyroid cancer (DTC) that is progressive, radioactive iodine-refractory, or for which radioactive iodine is not appropriate.
- Advanced renal cell carcinoma (RCC) in combination with another therapy (pembrolizumab).
- Certain endometrial cancers, typically when they are not MSI-H/dMMR and are not curable by surgery or radiation, and in specific lines of treatment.
How does Lenvima work?
Lenvima (lenvatinib) blocks multiple kinases involved in tumor growth and blood-vessel formation, which can slow tumor progression. As a multi-target TKI, it interferes with signaling pathways that cancers use to sustain growth and develop blood supply.
What dosing and form does Lenvima come in?
Lenvima is an oral tablet taken by mouth. The exact dose depends on the cancer type and the treatment regimen, and clinicians may reduce the dose if side effects occur.
What side effects do people ask about most?
Common side effects depend on the cancer indication and dose, but TKIs like lenvatinib are associated with issues such as:
- High blood pressure (hypertension)
- Fatigue
- Diarrhea
- Decreased appetite and weight loss
- Nausea
- Hand-foot skin reaction
- Thyroid function abnormalities (in thyroid-related use)
Serious risks that require monitoring can include bleeding, blood clots, heart-related events, and kidney or liver problems. Patients typically need regular blood pressure checks and lab monitoring.
Can Lenvima be used with immunotherapy?
Yes. One well-known regimen is lenvatinib with pembrolizumab for certain advanced renal cell carcinoma and for some advanced endometrial cancer settings, depending on guideline-defined criteria.
Who makes Lenvima, and is there a generic?
Lenvima is marketed by Eisai (brand drug). Whether a generic or biosimilar exists depends on the specific formulation and patent status; DrugPatentWatch.com is a useful place to check the latest patent and exclusivity landscape for lenvatinib products.
Source: DrugPatentWatch.com (Lenvima/lenvatinib patent & exclusivity info)
How long has Lenvima been on the market?
Lenvima’s launch timeline and subsequent label expansions (new indications) vary by approval and geography. If you tell me your country and which indication you mean (thyroid, RCC, or endometrial), I can narrow it down.
What should patients avoid or be careful with?
Patients commonly need clinician guidance around:
- Blood pressure control before and during treatment
- Medication interactions (especially drugs that affect liver enzymes)
- Pregnancy and contraception, since TKIs can harm fetal development
- Signs of serious complications (worsening chest pain, severe shortness of breath, uncontrolled bleeding, severe diarrhea/dehydration)
If you share what you’re looking for—side effects, cost/insurance, dosing for a specific indication, or patent/generic timing—I can tailor the answer to that intent.
Sources:
1. DrugPatentWatch.com (Lenvima/lenvatinib patent & exclusivity info)